SEC Company Response from ADEZA BIOMEDICAL CORP (CIK 0000902482) — Dec 6, 2004
ADEZA BIOMEDICAL CORP (CIK 0000902482)
Date: Dec. 6, 2004 · CIK: 0000902482 · Accession: 0000891618-04-001366
AI Filing Summary & Sentiment
File numbers found in text: 333-118012
Letter
UBS SECURITIES LLC
SG COWEN & CO., LLC
THOMAS WEISEL PARTNERS LLC
WILLIAM BLAIR & COMPANY, L.L.C.
c/o UBS Securities LLC
299 Park Avenue
New York, NY 10171
December 6, 2004
3,750,000 Shares
ADEZA BIOMEDICAL CORPORATION
Common Stock
Securities and Exchange Commission
450 Fifth Street, NW
Washington, DC 20549
Attn: Mr. Gregory S. Belliston
Ladies and Gentleman:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned, as the representatives of the prospective Underwriters of the above-captioned Shares, hereby join in the request of Adeza Biomedical Corporation that the effectiveness of the Registration Statement on Form S-1 relating to such Shares (Registration No. 333-118012) be accelerated so that the Registration Statement will become effective by 2:30 p.m. Eastern Time on December 9, 2004 or as soon thereafter as practicable.
Very truly yours,
UBS SECURITIES LLC
SG COWEN & CO., LLC
THOMAS WEISEL PARTNERS LLC
WILLIAM BLAIR & COMPANY, L.L.C.
By: UBS SECURITIES LLC
By: /s/ Carin Fradin
Name: Carin Fradin
Title: Director
By: /s/ Ankur Kamalia
Name: Ankur Kamalia
Title: Director
December 6, 2004
Securities and Exchange Commission
450 Fifth Street, NW
Washington, D.C. 20549
Attn: Mr. Gregory S. Belliston
Re: 3,750,000 Shares
Adeza Biomedical Corporation
Common Stock
Ladies and Gentlemen:
In connection with the request for acceleration of the effectiveness of the Registration Statement (Registration No. 333-118012) relating to the above-captioned Shares, please be advised that we have effected to date approximately the following distribution of the Preliminary Prospectus dated November 24, 2004:
to
institutions
13,500
to
prospective underwriters
to
others
Very truly yours,
UBS SECURITIES LLC
Show Raw Text
CORRESP
1
filename1.htm
corresp
UBS SECURITIES LLC
SG COWEN & CO., LLC
THOMAS WEISEL PARTNERS LLC
WILLIAM BLAIR & COMPANY, L.L.C.
c/o UBS Securities LLC
299 Park Avenue
New York, NY 10171
December 6, 2004
3,750,000 Shares
ADEZA BIOMEDICAL CORPORATION
Common Stock
Securities and Exchange Commission
450 Fifth Street, NW
Washington, DC 20549
Attn: Mr. Gregory S. Belliston
Ladies and Gentleman:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the
undersigned, as the representatives of the prospective Underwriters of the
above-captioned Shares, hereby join in the request of Adeza Biomedical
Corporation that the effectiveness of the Registration Statement on Form S-1
relating to such Shares (Registration No. 333-118012) be accelerated so that
the Registration Statement will become effective by 2:30 p.m. Eastern Time on
December 9, 2004 or as soon thereafter as practicable.
Very truly yours,
UBS SECURITIES LLC
SG COWEN & CO., LLC
THOMAS WEISEL PARTNERS LLC
WILLIAM BLAIR & COMPANY, L.L.C.
By:
UBS SECURITIES LLC
By:
/s/
Carin Fradin
Name:
Carin Fradin
Title:
Director
By:
/s/ Ankur Kamalia
Name:
Ankur Kamalia
Title:
Director
December 6, 2004
Securities and Exchange Commission
450 Fifth Street, NW
Washington, D.C. 20549
Attn: Mr. Gregory S. Belliston
Re:
3,750,000 Shares
Adeza Biomedical Corporation
Common Stock
Ladies and Gentlemen:
In connection with the request for acceleration of the effectiveness of
the Registration Statement (Registration No. 333-118012) relating to the
above-captioned Shares, please be advised that we have effected to date
approximately the following distribution of the Preliminary Prospectus dated
November 24, 2004:
531
to
381
institutions
13,500
to
4
prospective underwriters
0
to
0
others
Very truly yours,
UBS SECURITIES LLC
SG COWEN & CO., LLC
THOMAS WEISEL PARTNERS LLC
WILLIAM BLAIR & COMPANY, L.L.C.
By:
UBS SECURITIES LLC
By:
/s/
Carin Fradin
Name:
Carin Fradin
Title:
Director
By:
/s/
Ankur Kamalia
Name:
Ankur Kamalia
Title:
Director